茶碱-2-氨基乙醇 | 573-41-1

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 茶碱-2-氨基乙醇
• 英文名称: Theophylline olamine
• 英文别名: 2-aminoethanol;1,3-dimethyl-7H-purine-2,6-dione
• CAS: 573-41-1
• 化学式: C9H15N5O3
• 分子量: 241.25
• InChiKey: DAAFJZUNCOXSKD-UHFFFAOYSA-N

物化性质

• 熔点：
  255-260 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  茶碱 、 C.I.酸性橙108 生成 茶碱-2-氨基乙醇
  参考文献：
  名称：

  URQUHART, J.;THEEUWES, F.

  摘要：

  DOI：

文献信息

• Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use
  申请人：R.P. SCHERER CORPORATION

  公开号：EP0098041A2

  公开（公告）日：1984-01-11

  A preparation for pharmaceutical use, especially in the treatment of migraine, arthritis and bronchial complaints contains a sesquiterpene lactone and may be an extract recovered from the plant Tanacetum parthenium by extraction using a non-polar solvent. Alternatively the preparation may be a sesquiterpene lactone per se or formulation containing it.

  一种药物制剂，尤其是用于治疗偏头痛、关节炎和支气管疾病的制剂，含有倍半萜内酯，可以是从植物丹参（Tanacetum parthenium）中通过使用非极性溶剂萃取得到的提取物。 或者，该制剂本身就是倍半萜内酯或含有倍半萜内酯的制剂。
• Plurality of tiny pills in liquid dosage form
  申请人：ALZA CORPORATION

  公开号：EP0313992A1

  公开（公告）日：1989-05-03

  A delivery system is disclosed for delivering a beneficial agent to an environment of use. The delivery system comprises a plurality of tiny dosage forms comprising a beneficial agent. The delivery system also comprises means for maintaining (a) the physical and chemical integrity of the dosage forms and for (b) inhibiting delivery of the beneficial agent during non-performance of the delivery system.

  本发明公开了一种输送系统，用于向使用环境输送有益制剂。该给药系统包括多种微小剂型，其中包含一种有益药剂。递送系统还包括用于保持（a）剂型的物理和化学完整性和（b）在递送系统不工作期间抑制有益药剂递送的装置。
• Controlled release dosage forms having a defined water content
  申请人：Euroceltique S.A.

  公开号：EP0344960A2

  公开（公告）日：1989-12-06

  A controlled release, solid, oral dosage form containing a 3-alkylxanthine, preferably theophylline, at least one hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25° and 90°C and between 3% and 10% (by weight) water. Preferably the dosage form is a tablet and the water content is between 4% and 9% (by weight). The amount of water present in the dosage form determines the rate of release of the 3-alkylxanthine.

  一种控释固体口服剂型，含有一种 3-烷基黄嘌呤（最好是茶碱）、至少一种亲水性或疏水性聚合物、至少一种熔点在 25°至 90°C 之间的蜡以及 3%至 10%（按重量计）的水。 剂型最好是片剂，含水量在 4%至 9%（重量比）之间。剂型中的含水量决定了 3-烷基黄嘌呤的释放速度。
• Sustained release tablet comprising pramipexole
  申请人：Pharmacia Corporation

  公开号：EP2172199A1

  公开（公告）日：2010-04-07

  A sustained - release pharmaceutical composition in a form of an orally deliverable tablet comprising an active pharmaceutical agent having solubility not less than about 10mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15kNcm-2 at a solid fraction representative of the tablet.

  一种口服给药片剂形式的缓释药物组合物，包含溶解度不小于约 10 毫克/毫升的活性药剂，分散在由亲水性聚合物和淀粉组成的基质中，在片剂的代表性固体部分拉伸强度至少约为 0.15 千牛顿厘米-2。
• Methylxanthines in the diagnosis and treatment of autistic disorder
  申请人：——

  公开号：US20020019407A1

  公开（公告）日：2002-02-14

  The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.

  本发明基于以下发现：与正常儿童相比，确诊有自闭症症状的儿童尿样中一种或多种甲基黄嘌呤的含量明显降低，而自闭症儿童尿样中黄嘌呤的含量升高。因此，尿液中甲基黄嘌呤含量低于一定范围，黄嘌呤含量高于一定范围，可诊断为自闭症。另一方面，这些甲基黄嘌呤中的一种或多种可用于治疗表现出自闭症症状的个体。